<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
| **PROS-14** Internal request: Institutional Review: Consider the inclusion of apalutamide as a systemic therapy option for the treatment of metastatic castration-naïve prostate cancer regardless of volume/risk. (also applies to PROS-F)  
External request: Submission for Janssen Biotech, Inc. requesting inclusion of apalutamide with a category 1 evidence level rating for systemic therapy for metastatic castration-naïve prostate cancer. (also applies to PROS-F) | Based on the data in the noted references and discussion, the panel consensus was to include apalutamide as a systemic therapy option for metastatic castration-naïve prostate cancer. This is a category 1 recommendation.  
See Submission for Reference. | 15 0 3 11 |
| **PROS-14** Institutional Review: Consider the inclusion of enzalutamide as a systemic therapy option for the treatment of metastatic castration-naïve prostate cancer regardless of volume/risk. (also applies to PROS-F)  
External request: Submission from Astellas Pharma Global Development, Inc. requesting inclusion of enzalutamide plus androgen deprivation therapy in men with metastatic castration-naïve prostate cancer, regardless of prior docetaxel use or disease volume. | Based on the data in the noted references and discussion, the panel consensus was to include enzalutamide as a systemic therapy option for metastatic castration-naïve prostate cancer. This is a category 1 recommendation.  
See Submission for Reference. | 16 0 2 11 |
**PROS-15**  
Internal request: Consider darolutamide for nonmetastatic castration-resistant prostate cancer as level 1 evidence. (also applies to PROS-F)

In response to the FDA approval of darolutamide for the treatment of non-metastatic castration-resistant prostate cancer, the panel voted on the addition of darolutamide for this indication.

Based on the data in the noted references and discussion, the panel consensus was to include darolutamide as a systemic therapy option for non-metastatic castration-naïve prostate cancer. This is a category 1 recommendation.


| 16 | 0 | 1 | 12 |